[1] Vivek C G,Mais K,Christopher J B,et al. Efficacy of probiotics in irritable bowel syndrome:systematic review and meta-analysis[J]. Gastroenterology,2023,165(5):1206-1218.
[2] Saleem M M,Masood S,Rahmatullah M M,et al.Gut microbiota dysbiosis and its role in the development of irritable bowel syndrome[J]. Cureus, 2025,17(4):e83084.
[3] Liang F,Ying L,Jia L,et al. Gut microbiota and the “gut-livet-kidnen axis”theroy:from mechanisms to therapeutis[J].Microbiology,2025,16(7):1554458.
[4] Cheng X Y, Ren C, Mei X F,et al. Gut microbiota and irritable bowel syndrome:status and prospect[J]. Medicine,2024,11(10):1429133.
[5] Li E F,Wang J,Guo B. et al. Effects of short-chain fatty acid-producing probiotic metabolites on symptom relief and intestinal barrier function in patients with irritable bowel syndrome:a double-blind, randomized controlled trial[J]. Front Cell Infect Microbiol,2025,15(7):1616066.
[6] María J M,Mrria J S,Andrea R L,et al. Exploring gut microbiota imbalance in irritable bowel syndrome:potential therapeutic effects of probiotics and their metabolites[J]. Nutrients,2025,17(1):155.
[7] Bertuccioli A, Sisti D, Lazzerini N, et al. Targeted probiotic therapy in irritable bowel syndrome: a clinical evaluation on Clostridium butyricum CBM588 and Bifidobacterium longum W11[J]. Front Med (Lausanne),2025,12(5):1604319.
[8] Choi Y, Youn Y H, Kang S J, et al.Korean society of neurogastroenterology and motility. 2025 seoul consensus on clinical practice guidelines for irritable bowel syndrome[J]. J Neurogastroenterol Motil,2025,31(2):133-169.
[9] Lee K N, Lee O Y. Intestinal microbiota in pathophysiology and management of irritable bowel syndrome[J]. World J Gastroenterol,2014,20(27):8886-8897.
[10] Distrutti E, Monaldi L, Ricci P, et al. Gut microbiota role in irritable bowel syndrome: new therapeutic strategies[J]. World J Gastroentero,2016,22(7):2219-2241.
[11] Jyoti D P. Mechanisms and implications of the gut microbial modulation of intestinal metabolic processes[J]. NPJ Metab Health Dis,2025,3(1):24.
[12] Laterza L, Cremon C, Coppola G, et al. Multistrain probiotics plus vitamin d improve gut barrier function and gut microbiota composition in irritable bowel syndrome without constipation: results from a double-blind, randomized, placebo-controlled trial[J]. Nutrients, 2025,17(10):1708.
[13] 李灵剑,张兴光,刘铭君,等. 缺氧诱导的肠道损伤与IBS的可能关系[J].武警医学,2024,35(3):243-247.
[14] 胡 玥, 陶丽媛, 吕 宾. 益生菌制剂治疗肠易激综合征的Meta分析[J]. 中华内科杂志, 2015, 54(5): 445-451.
[15] Xie H, Yu S, Tang M, et al. Gut microbiota dysbiosis in inflammatory bowel disease: interaction with intestinal barriers and microbiota-targeted treatment options[J]. Front Cell Infect Microbiol, 2025,15(7):1608025.
[16] 唐曼玉,王晚晴,强敬雯,等. 益生菌与肠道菌群、免疫调节的相互作用与机制研究进展[J]. 食品工业科技,2022,43(16):486-493.
[17] Cheng X, Ren C, Mei X, et al. Gut microbiota and irritable bowel syndrome: status and prospect[J]. Front Med (Lausanne),2024,11(10):1429133.
[18] Shaikh S D, Sun N, Canakis A, et al. Irritable bowel syndrome and the gut microbiome: a comprehensive review[J]. J Clin Med,2023,12(7):2558.
[19] Yang R W,Jiang J W,Ouyang J,et al. Efficacy and safety of probiotics in irritable bowel syndrome:a systematic review and meta-analysis[J]. Clin Nutr ESPEN,2024,60(4):362-372.
[20] Zeng Q, Li P, Wu H,et al.Probiotics and gastrointestinal disorders: an umbrella meta-analysis of therapeutic efficacy[J].Eur J Med Res, 2025,30(1)515-646.
[21] Konstantis G, Efstathiou S, Pourzitaki C, et al. Efficacy and safety of probiotics in the treatment of irritable bowel syndrome: a systematic review and meta-analysis of randomised clinical trials using ROME IV criteria[J]. Clin Nutr,2023,42(5):800-809.
[22] Dale H F, Rasmussen S H, Asiller ÖÖ, et al. Probiotics in irritable bowel syndrome: an up-to-date systematic review[J]. Nutrients,2019,11(9):2048.
[23] Whorwell P J, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis35624 in women with irritable bowel syndrome[J].Am J Gastroenterol,2006,101(7):1581-1590.
[24] Guarner F, Sanders M　E, Szajewska H, et al. World Gastroenterology Organisation global guidelines: probiotics and prebiotics[J]. J Clin Gastroenterol,2024,58(6):533-553.
[25] Ruiz S C, Escudero L B, Fernández P S. Evaluation of the efficacy of probiotics as treatment in irritable bowel syndrome[J]. Endocrinol Diabetes Nutr (Engl Ed),2024,71(1):19-30.
[26] Puebla B S, Reid G. Forty-five-year evolution of probiotic therapy[J]. Microb Cell,2019, 6(4):184-196.
[27] Giorgio V, Quatrale G, Mennini M, et al.Bifidobacterium adolescentis PRL 2019 in pediatric irritable bowel syndrome: a multicentric, randomized, double-blind, placebo-controlled trial[J]. Microorganisms,2025,13(3):627.
[28] Niedzielin K, Kordecki H, Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome[J]. Eur J Gastroenterol Hepatol,2001,13(10):1143-1147.
[29] Ducrotté P, Sawant P, Jayanthi V. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome[J]. World J Gastroenterol,2012,18(30):4012-4018.
[30] Horvath A, Dziechciarz P, Szajewska H. Meta-analysis: Lactobacillus rhamnosus GG for abdominal pain-related functional gastrointestinal disorders in childhood[J]. Aliment Pharmacolher,2011,33(12):1302-1310.
[31] 刘 洋, 郁辛杰, 于雷雷,等. 植物乳杆菌CCFM8610缓解肠易激综合征并改善肠道菌群失调,一项随机、双盲、安慰剂对照的先导性临床试验[J].工程(英文), 2021, 7(3): 376-385.
[32] McFarland LV, Dublin S.Meta-analysis of probiotics for the treatment of irritable bowel syndrome[J].World J Gastroenterol,2008,14(17): 2650-2661.
[33] Choi M D, Sun Y M D,Park M D, et al. A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life[J].J Clin Gastroenterol,2011,45(8):679-683.
[34] Abbas Z, Yakoob J, Jafri W, et al. Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: a randomized trial[J]. Eur J Gastroenterol Hepatol,2014,26(6):630-639.
[35] Wu Y, Li Y, Zheng Q, et al. The efficacy of probiotics, prebiotics, synbiotics, and fecal microbiota transplantation in irritable bowel syndrome: a systematic review and network meta-analysis[J]. Nutrients,2024,16(13):2114.
[36] Laterza L, Cremon C, Coppola G, et al. Multistrain probiotics plus vitamin D improve gut barrier function and gut microbiota composition in irritable bowel syndrome without constipation: results from a double-blind, randomized, placebo-controlled trial[J]. Nutrients,2025,17(10):1708.
[37] Aah S, Akbari A, Heshmati J, et al. Systematic review with meta-analysis: effects ofprobiotic supplementation on symptoms in functional dyspepsia[J].J Funct Foods,2020,30(11):68-76.
[38] 李贵敏,陈 平. 益生菌治疗肠易激综合征临床疗效的系统分析[J].内蒙古医科大学学报,2022,44(5):449-453
[39] Yang R, Jiang J, Ouyang J, et al. Efficacy and safety of probiotics in irritable bowel syndrome: A systematic review and meta-analysis[J]. Clin Nutr Espen,2024,60(4):362-372.
[40] 中华预防医学会微生态学分会,中国医师协会感染科医师分会.中国微生态调节剂临床应用专家共识(2025版)[J].中国微生态学杂志,2025,37(8):873-874
[41] Mcfarland L V, Karakan T, Karataş A.Strain-specific and outcome-specific efficacy of probiotics for the treatment of irritable bowel syndrome: a systematic review and meta-analysis[J].Mcfarland,2021,41(10):1154.
[42] Lei Y, Sun X, Ruan T, et al. Effects of probiotics and diet management in patients with irritable bowel syndrome: a systematic review and network meta-analysis[J]. Nutr Rev,2025, 83(9):1743-1756.
[43] Vasant D H, Paine P A, Black C J, et al. British society of gastroenterology guidelines on the management of irritable bowel syndrome[J]. Gut,2021,70(7):1214-1240.
[44] Fukudo S, Okumura T, Inamori M, et al. Evidence-based clinical practice guidelines for irritable bowel syndrome 2020[J]. J Gastroenterol,2021,56(3):193-217.
[45] Guarner F, Sanders M E, Szajewska H, et al. World gastroenterology organisation global guidelines: probiotics and prebiotics[J]. J Clin Gastroenterol,2024,58(6):533-550.
[46] Farland L V, Dublin S.Meta-analysis of probiotics for the treatment of irritable bowel syndrome[J].World J Gastroenterol,2008,14(17): 2650-2661.
[47] Hong S N, Rhee P L.Unraveling the ties between irritable bowel syndrome and intestinal microbiota[J].World J Gastroenterol,2014,20(10): 2470-2481.
[48] Bertuccioli A, Sisti D, Lazzerini N, et al. Targeted probiotic therapy in irritable bowel syndrome: a clinical evaluation on clostridium butyricum CBM588 and Bifidobacterium longum W11[J]. Front Med (Lausanne),2025,12(5):1604319.
[49] Guglielmetti S, Mora D, Gschwender M, et al. Randomised clinical trial: bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study[J]. Aliment Pharmacol Ther,2011,33(10):1123-1132.
[50] Martoni C J, Srivastava S, Damholt A, et al. Efficacy and dose response of lactip lantibacillus plantarumin diarrhea-predominant irritable bowel syndrome[J]. World J Gastroenterol,2023,29(28):4451-4465.
[51] Kajander K, Myllyluoma E, Rajilic S M,et al. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota[J]. Aliment Pharmacol Ther,2008,27(1):48-57.